Evidence map›Paper›PMID 36656536›Full record

ArticleApplied biochemistry and biotechnology2023

Bladder Cancer Progression Is Suppressed Through the Heart and Neural Crest Derivatives Expressed 2-Antisense RNA 1/microRNA-93-5p/Defective in Cullin Neddylation 1 Domain Containing 3 Axis.

Xiang Wu, Qingjiang Xu, Tao Li, Yongbao Wei, Rong Zeng, Rongcheng Lin, Lina Xu, Liefu Ye, Zhihua Liu

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Xiang Wu *Provincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Qingjiang Xu *Provincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Tao LiProvincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Yongbao WeiProvincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Rong ZengProvincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Rongcheng LinProvincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Lina XuProvincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China.
Liefu YeProvincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. yelielflf@163.com.
Zhihua LiuProvincial Clinical Medical College of Fujian Medical University, Fuzhou, 350001, China. liuzhihua_lzh11@163.com.
Fujian Medical University · CN

Funding

High-level hospital foster grants from Fujian Provincial Hospital, Fujian Province, China 2020HSJJ13Startup Fund for scientific research, Fujian Medical University 2019QH1175
6 · The paper itself

Abstract

MicroRNAs (miRNAs) are critical in progression of bladder cancer (BCa). miRNA-93-5p is increased in cancers and is positively correlated with an unfavorable prognosis. But its effects on BCa remain rarely understood. This investigation aimed to dig out miRNA-93-5p affecting biological behaviors of BCa. In this research, mRNA and protein expression in cancer cells were assessed via quantitative real-time polymerase chain reaction (qRT-PCR) and western blot. Cell Counting Kit-8 (CCK-8), colony formation, scratch healing, and transwell assays were utilized to analyze cancer cell viability, colony-forming, migration, and invasion, respectively. Bioinformatics analysis predicted upstream regulatory genes and downstream target genes of miRNA-93-5p, with the targeting relationship being verified through a dual-luciferase assay. The BCa xenograft model in nude mice further investigated the effect of miRNA-93-5p and AND2-AS1 on tumor size and quality, and validated the relationship between HAND2-AS1/miRNA-93-5p/DCUN1D3. Our results displayed that miRNA-93-5p was increased in BCa cell lines. Knockdown miRNA-93-5p constrained BCa cell malignant phenotypes. HAND2-AS1 targeted miRNA-93-5p, thus restraining malignant progression of BCa cells. DCUN1D3 was found downstream of miRNA-93-5p. miRNA-93-5p modulated proliferation, migration, and invasion of BCa cells by targeting DCUN1D3. In vivo experiments disclosed that forced expression of lncRNA HAND2-AS1, and inhibited miRNA-93-5p regressed tumor growth. Meanwhile, the same as the results of cell experiments, the expression of miRNA-93-5p was downregulated, and DCUN1D3 expression was advanced in tumor tissues. To conclude, lncRNA HAND2-AS1 exerted anti-tumor effects and regulated BCa cell proliferation, invasion, and migration by targeting miRNA-93-5p/DCUN1D3.

Indexed as

MicroRNAsRNA, Long NoncodingUrinary Bladder NeoplasmsAnimalsCell Cycle ProteinsCell Line, TumorCell MovementCell ProliferationCullin ProteinsGene Expression Regulation, NeoplasticHumansMiceMice, NudeNeural CrestRNA, AntisenseCell Cycle ProteinsCullin ProteinsDCUN1D3 protein, humanlong non-coding RNA HAND2-AS1, humanMicroRNAsMIRN93 microRNA, humanRNA, AntisenseRNA, Long NoncodingBladder cancerDCUN1D3lncRNA HAND2-AS1miRNA-93-5pProgression

Identifiers

PMID36656536
OpenAlexW4317423833

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.